
Edgar Filing: Hagan Joseph P - Form 4

Hagan Joseph P Form 4 March 02, 2018		
FORM 4 UNITED	STATES SECURITIES AND EXCH	OMB APPROVAL
Check this box	Washington, D.C. 2054	9 Number: 3235-0287
Section 16. Form 4 or Form 5 Filed put	IENT OF CHANGES IN BENEFIC SECURITIES suant to Section 16(a) of the Securities	IAL OWNERSHIP OF burden hours per response 0.5
obligations may continue. Section 17(See Instruction 1(b).	a) of the Public Utility Holding Comp 30(h) of the Investment Company	•
(Print or Type Responses)		
1. Name and Address of Reporting Hagan Joseph P	Person [*] 2. Issuer Name and Ticker or Tr Symbol Zosano Pharma Corp [ZSA]	Issuer
(Last) (First) (Middle) 3. Date of Earliest Transaction	(Check all applicable)
C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT	(Month/Day/Year) 01/02/2018	X_ Director 10% Owner Officer (give title Other (specify below) below)
(Street) FREMONT, CA 94555	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting
(City) (State)	(Zip) Table I - Non-Derivative Sec	Person urities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed 3. 4. Securities	5. Amount of 6. Ownership 7. Nature of or Securities Form: Direct Indirect D) Beneficially (D) or Indirect Beneficial d 5) Owned (I) Ownership Following (Instr. 4) (Instr. 4) Reported Transaction(s) (Instr. 3 and 4)
Reminder: Report on a separate line	for each class of securities beneficially owned	directly or indirectly.
	informat required	who respond to the collection of on contained in this form are not to respond unless the form a currently valid OMB controlSEC 1474 (9-02)
Tab	e II - Derivative Securities Acquired, Dispos (e.g., puts, calls, warrants, options, con	
	action Date 3A. Deemed 4. 5 Day/Year) Execution Date, if Transaction	Number of erivative6. Date Exercisable and Expiration Date7. Title and Amount Underlying Securitie

Edgar Filing: Hagan Joseph P - Form 4



Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Hagan Joseph P C/O ZOSANO PHARMA CORPORATION 34790 ARDENTECH COURT FREMONT, CA 94555	Х				
Signatures					
/s/ Jeffrey L. Quillen, attorney-in-fact	/02/2018				

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) As a result of a 1-for-20 reverse stock split of the common stock of the Company, which became effective at 5:00 p.m. Eastern Time on January 25, 2018 (the "Reverse Split"), the exercise price has increased from \$0.53 per share to \$10.60 per share.
- (2) As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares.
- (3) The shares underlying the option shall vest on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S

(